

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|----|---|
| (51) International Patent Classification 6 : | A1 | (11) International Publication Number: WO 99/24407 |
| C07D 235/16, 209/18, 209/42, 333/60, 333/62, 235/14, 209/08, 401/12, 403/12, 409/12, C07C 257/18, A61K 31/155, 31/40, 31/415, 31/38 | | (43) International Publication Date: 20 May 1999 (20.05.99) |

| | |
|--|--|
| (21) International Application Number: PCT/US98/23362 | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). |
| (22) International Filing Date: 3 November 1998 (03.11.98) | |
| (30) Priority Data: 60/065,154 10 November 1997 (10.11.97) US 09/179,695 27 October 1998 (27.10.98) US | |
| (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). | |
| (72) Inventors: BURGESS, Laurence; 5617 Slick Rock Court, Boulder, CO 80301 (US). RIZZI, James, P.; 7180 Longview Drive, Niwot, CO 80503 (US). | Published <i>With international search report.</i> |
| (74) Agents: ODRE, Steven, M. et al.; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). | |

(54) Title: COMPOUNDS WHICH INHIBIT TRYPTASE ACTIVITY

(57) Abstract

The present invention is directed to compounds which are capable of inhibiting the activity of tryptase. Such compounds are useful in the treatment or prevention of inflammatory disease, particularly those disease states which are mediated by mast cell activation. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds and methods for treating or preventing an inflammatory disease.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | VN | Viet Nam |
| CF | Central African Republic | JP | Japan | NL | Netherlands | YU | Yugoslavia |
| CG | Congo | KE | Kenya | NO | Norway | ZW | Zimbabwe |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | | |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

- 1 -

Title

COMPOUNDS WHICH INHIBIT TRYPTASE ACTIVITY

5 Field of the Invention

This invention relates to anti-inflammatory and anti-allergy agents and, more particularly, relates to novel compounds, formulations and methods for the prophylaxis and treatment of inflammation, allergy and 10 pulmonary disorders. The invention particularly relates to compositions and methods that are efficacious for the treatment of tryptase-related and mast cell mediated inflammatory disorders.

15 Background of the Invention

The disorders noted above include, among others, asthma and other inflammatory diseases of the pulmonary system like allergic rhinitis, chronic obstructive pulmonary disease, respiratory syncytial 20 virus and smoker's emphysema where the methods and compositions described herein are useful. Furthermore, the compositions and methods are particularly useful in treating the underlying pathological changes in the airways associated with these diseases such as basement 25 membrane thickening, cell hypertrophy and hyperplasia, inflammatory cell influx, and other tissue remodeling. Other inflammatory conditions, including, for example, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, conjunctivitis, psoriasis, scleroderma, 30 and related diseases can be treated with the compounds and methods described herein.

To better understand the invention, the following brief description of mast cell mediated disease, particularly asthma, is provided. Human asthma 35 is a complex inflammatory disease. Genetic susceptibility and repeated allergen exposure from a

variety of sources lead to allergen sensitization that, via IL-4 production from T-cells and mast cells, can ultimately induce B-cell derived IgE levels that are significantly elevated over normal levels. Subsequent 5 exposure to allergen coupled with these newly elevated IgE levels can activate the Fc ϵ RI high affinity IgE receptor on the surface of mast cells and other pro-inflammatory cells in the lung to induce degranulation/activation and thus trigger a cascade of 10 inflammatory responses. This early phase of the response is characterized by severe bronchoconstriction that reaches its peak at about 15 minutes followed by a recovery of several hours. Many pre-formed substances are immediately released from the mast cell including 15 histamine, heparin, cytokines (including, for example, IL-3, IL-4, IL-5, IL-6, and TNF- α), and proteases (including, for example, cathepsin G, chymase, carboxy peptidase A, tryptase). In relation to these other proteases, tryptase is released in very large amounts 20 up to 35 pg per cell (see Caughey, Am. J. Physiol., 257, L39-46 (1989) and Walls in "Asthma and Rhinitis" 1995, pp. 801-824). Furthermore, tryptase is long lived, and has been shown to have a myriad of significant effects as a peptidase, protease and 25 cytokine that intensify the inflammatory response. For example, tryptase can cause further mast cell degranulation to amplify the allergen response (see Molinari et al., J. Appl. Physiol., 79(6), 1966-70 (1995)) and induce eosinophil and neutrophil migration 30 into the lung (see Walls et al., Int. Arch. Allergy Immunol., 107, 372-3 (1995)). Also, tryptase can inactivate fibrinogen to act as a local anti-coagulant and promotes plasma extravasation bringing more circulating cells and mediators into the lung (see 35 Schwartz et al., J. Immunol., 135, 2762-7 (1985)).

-3-

Further, tryptase can process high and low molecular weight kininogen to bradykinin and activates kallikrein to produce neurogenic inflammation (see Proud *et al.*, *Biochem. Pharm.*, 37(8), 1473-80 (1988); Walls *et al.*, *Biochem. Soc. Trans.*, 20, 260S (1992); Imamura *et al.*, *Lab. Invest.*, 74, 861-70 (1996)) while degrading neurogenic feedback mechanisms like the bronchodilatory neuropeptides (for example, VIP, peptide histidine methionine and peptide histidine isoleucine) and further promote mucous secretion and bronchoconstriction (see Tam and Caughey, *Am. J. Respir. Cell Mol. Biol.*, 3, 27-32 (1990)). Tryptase can amplify the effects of histamine to further enhance bronchoconstriction (see Molinari *et al.*, *J. Appl. Physiol.*, 79(6), 1966-70 (1995); Sekizawa *et al.*, *J. Clin. Invest.*, 83, 175-9 (1989); Johnson *et al.*, *Eur. Respir. J.*, 10, 38-43 (1997)). Tryptase is a mitogen/activator of fibroblast (see Ruoss *et al.*, *J. Clin. Invest.*, 88, 493-9 (1991); Gruber *et al.*, *J. Immunology*, 158, 2310-17 (1997)) and bronchial smooth muscle cells which can contribute to airway hyperresponsiveness to the lung as seen in a variety of pulmonary disorders (see Brown *et al.*, *Chest*, 107(3), 95-6S (1995); Caughey *et al.*, *Am. J. Respir. Cell Mol. Biol.*, 13, 227-36 (1995)). Further, tryptase is a mitogen for airway epithelial cells and induces IL-8 and ICAM-1 expression (see Cairns and Walls *J. Immunology*, 156, 275-83 (1996)) and recently tryptase has been shown to activate cellular receptors (see Molino *et al.*, *J. Biol. Chem.*, 272(7), 4043-49 (1997)).

Following this early mast cell degranulation and release of tryptase, the activation of the arachidonic acid cascade resulting in the production of lipid mediators, such as the leukotrienes (LTD4, LTC4, LTE4, LTB4), the prostaglandins (PGD2) and platelet

activating factor (PAF), occurs several minutes later. Six to twelve hours after initial allergen exposure, a late phase inflammatory response takes place in which bronchoconstriction is again visited upon the 5 asthmatic. By this time the mast cell has begun to produce protein mediators like the cytokines (IL-1,3,4,5,6), chemokines (IL-8, MIP-1 α) and growth factors (GM-CSF). This late phase response is associated with a significant influx of inflammatory 10 cells, most notably eosinophils, neutrophils, and lymphocytes, into the lung tissue and airway space. These cells are activated and release even more mediators which can contribute to the significant tissue damage and development of hyperresponsiveness 15 seen in chronic asthma.

The various activities of tryptase contribute to the early and late phase bronchoconstriction as well as to the development of airway hyperresponsiveness, a hallmark of asthma. Furthermore, in chronic asthma and 20 other long term respiratory diseases, these activities cause profound changes to the airway such as desquamation of the epithelial lining, fibrosis and thickening of the underlying tissues. These changes are not treated by present therapeutics.

25 Tryptase can be detected in a variety of biological fluids and recently tryptase's relatively long biological half-life (vis à vis histamine) has become appreciated and clinicians now use circulating levels of tryptase as a marker of anaphylaxis (see 30 Schwartz *et al.*, N. Engl. J. Med., 316, 1622-26 (1987)). Elevated levels of tryptase can be detected in lavage fluid from allergen challenged atopic asthmatics as well as in cigarette smokers, where there is significant lung damage (see Castells *et al.*, J. Allerg. Clin. Immunol., 82, 348-55 (1988); Wenzel *et* 35

-5-

al., Am. Rev. Resp. Dis., 141, 563-8 (1988);
Kalenderian et al., Chest, 94, 119-23 (1988)).

Tryptase can process prostromelysin to mature stromelysin (MMP-3) which can further activate 5 collagenase (MMP-1). Thus tryptase could play a significant role in the tissue remodeling of various pulmonary disorders (most notably asthma) but also in rheumatoid and osteo-arthritis.

Tryptase is stored in the mature form as a 10 homotetramer within the secretory granules of the mast cell and probably is held in an inactivated form by the low pH of this intracellular media. When released it is stabilized by interactions with heparin. This unique assembly of 4 catalytically active subunits could also 15 be considered to be a dimer of dimers because computational models indicate that two adjacent active sites may face one another.

Being a member of the tryptic-like serine 20 protease family, human tryptase prefers an arginine or lysine in the P1 subsite of a substrate. Because of this well recognized preference for basic residues at S1 there have been reports of inhibitors that incorporate physiologically protonated basic chemical moieties. (See, for example, benzamidines (see Caughey 25 et al., J. Pharm. Exp. Therap., 264, 676-82 (1993); Tidwell, et al., J. Med. Chem. 21(7), 613 (1978); Dominguez et al., WO 9801428 and references cited therein); benzguanidines, benzylamines (see Rice et al., WO 9609297); and, modified peptides incorporating 30 an arginine. (see Spear et al., WO 9420527)). (See also Lum, et al., WO 95/32945 (based on U.S. Ser. No. 08/252,099, filed June 1, 1994, now issued as U.S. Patent No. 5,656,660 (granted August 12, 1997)); Neises et al., U.S. Patent No. 5,391,705 (granted February 21, 35 1995); Neises et al., U.S. Patent No. 5,498,779 (granted March 12, 1996); Neises et al. EP A 0504064

- 6 -

(published September 16, 1992); Powers *et al.*, U.S. Patent No. 4,954,519 (granted September 4, 1990); Von der Saal *et al.*, WO 94/27958 (published December 8, 1994) and Spear *et al.*, U.S. Patent No. 5,525,623 5 (granted June 11, 1996)); .


Summary of the Invention

As noted, the present invention provides novel compounds which inhibit tryptase activity. Also 10 provided are formulations containing the novel compounds and methods of using the compounds to treat a patient in need thereof. More specifically, there are provided methods for the treatment of a patient suffering from a mast cell mediated disorder, including 15 for example, asthma, allergic rhinitis, rheumatoid arthritis, dermatological diseases, multiple sclerosis, conjunctivitis, inflammatory bowel disease, anaphylaxis, osteoarthritis, peptic ulcers, cardiovascular disease, or other disease state in which 20 mast cells and, in particular, tryptase activation is involved. In addition, there are described processes for preparing the inhibitory compounds of the invention.

The present invention relates to tryptase 25 inhibitors, pharmaceutically acceptable salts and prodrugs thereof useful in the treatment or prophylaxis of inflammatory diseases, particularly asthma and other related inflammatory diseases. The invention also encompasses pharmaceutical compositions and methods for 30 prophylaxis and treatment of asthma, pulmonary disorders and related inflammatory, mast-cell mediated diseases, particularly those which involve activation of tryptase. Also provided are processes for making such compounds as well as intermediates useful in such 35 processes.

Detailed Description of the Invention

As noted, the present invention provides
5 compounds useful for the treatment or prophylaxis of
inflammatory diseases. In particular, a compound of
Formula (I):



10 (I)

wherein

X is $-C(O)-$, $-(CH_2)_n-$ or $-SO_2-$;

R is $-H$, straight or branched chain (C_1-C_6) -alkyl, $-(C_1-C_6)$ -cycloalkyl or $-(CH_2)_m-Ar'- (Y),$;

15 Ar or Ar' is aryl, heteroaryl, or a 5-membered
to 7-membered carbocyclic or heterocyclic ring;

Y is $R^1HN-C(=NH)-$, $R^1HN-CO-NH-$, $N\equiv C-$ or $R^1HN-(CH_2)_v-$,
 (C_1-C_6) alkyl- SO_2NH- , $-SO_2NH_2$,
 (C_1-C_6) alkyl- $CONH-$, $-OH$, $-SH$, $-CF_3$, $-F$, $-Cl$,

20 $-Br$, $-I$, $-H$, $-O(C_1-C_6)$ alkyl, aryl,
 $-(C_1-C_6)$ alkylaryl, heteroaryl, (C_1-C_6) acyloxy,
 (C_1-C_6) alkyl, (C_1-C_6) alkylthio, $-NO_2$;

R^1 is $-H$, (C_1-C_4) alkyl- $O-CO-$, (C_1-C_4) alkyl- $O-$ or $HO-$;

j is an integer from 1 to 5, inclusive;

25 n is an integer between 0 and 10, inclusive;

m is an integer between 0 and 10, inclusive;

t is an integer from 1 to 5, inclusive;

v is an integer between 0 and 6, inclusive;

wherein which each Y, Ar, or Ar', is the same or
30 different, provided that if X is $-C(O)-$, then n is not
zero; or,

a pharmaceutically acceptable salt, ester, or solvate
thereof, is useful for the treatment or prophylaxis of
an inflammatory disease, particularly a mast-cell

- 8 -

mediated inflammatory disease, especially one in which tryptase is activated.

Preferred compounds of Formula (I) are those in which Ar and Ar' are independently, phenyl, indole, 5 naphthalene, benzothiophene, or benzimidazole, and in which Y is R¹HN-C(=NH)-.

The term "alkyl" refers to a univalent saturated, straight- or branched-chain alkyl group containing the designated number of carbon atoms. 10 Thus, the term "C₁-C₆ alkyl" refers to a univalent saturated, straight- or branched-chain alkyl group which can contain from one to six carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, n-pentyl, 2-methylbutyl, 3-methyl-15 butyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, and the like.

The term alkoxy refers to an alkyl group bonded through an oxygen atom to another substituent. 20 Thus, the term "C₁-C₄ alkoxy" refers to a C₁-C₄ alkyl group bonded through an oxygen atom to another substituent and includes, for example, methoxy, ethoxy, n-propoxy, n-butoxy, t-butoxy and isobutoxy.

The term "carbocyclic" refers to an organic 25 cyclic moiety in which the cyclic skeleton is comprised of only carbon atoms whereas the term "heterocyclic" refers to an organic cyclic moiety in which the cyclic skeleton contains one or more heteroatoms selected from nitrogen, oxygen, or sulfur and which may or may not 30 include carbon atoms.


Thus, the term "cycloalkyl" refers to a carbocyclic moiety containing the indicated number of carbon atoms. The term "C₃-C₈ cycloalkyl", therefore, refers to an organic cyclic substituent in which three 35 to eight carbon atoms form a three, four, five, or six, seven, or eight-membered ring, including preferably,

- 9 -

for example, a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring.

"Aryl" refers to an aromatic carbocyclic group having a single ring, for example, a phenyl ring, 5 multiple rings, for example, biphenyl, or multiple condensed rings in which at least one ring is aromatic, for example, naphthyl, 1,2,3,4,-tetrahydronaphthyl, anthryl, or phenanthryl, which can be unsubstituted or substituted with one or more substituents selected from 10 halogen, lower (C₁-C₄) alkyl, lower (C₁-C₄) alkoxy, lower (C₁-C₄) alkylthio, trifluoromethyl, lower (C₁-C₄) acyloxy, aryl, heteroaryl and hydroxy. The substituents attached to a phenyl ring portion of an 15 aryl moiety (*i.e.* either or both of Ar or Ar') in the compounds of Formula (I) may be configured in the ortho-, meta- or para- orientations, with the meta- and 20 para- orientations being preferred.

Examples of typical aryl moieties included in the scope of the present invention may include, but are not limited to, the following:



"Heterocycle" or "heterocyclic" refers to a saturated, unsaturated or aromatic carbocyclic group having a single ring, multiple rings or multiple 25 condensed rings, and having at least one hetero atom such as nitrogen, oxygen or sulfur within at least one


-10-

of the rings. "Heteroaryl" refers to a heterocycle in which at least one ring is aromatic. Any of the heterocyclic or heteroaryl groups can be unsubstituted or optionally substituted with one or more groups 5 selected from halogen, lower (C_1 - C_4) alkyl, lower (C_1 - C_4) alkoxy, lower (C_1 - C_4) alkythio, trifluoromethyl, lower (C_1 - C_4) acyloxy, and hydroxy.

As one skilled in the art will appreciate such heterocyclic moieties may exist in several 10 isomeric forms, all of which are to be encompassed by the present invention. For example, a 1,3,5-triazine moiety is isomeric to a 1,2,4-triazine group. Such positional isomers are to be considered within the scope of the present invention. Likewise, the 15 heterocyclic or heteroaryl groups can be bonded to other moieties in the compounds of the invention. The point(s) of attachment to these other moieties is not to be construed as limiting on the scope of the invention. Thus, by way of example, a pyridyl moiety 20 may be bound to other groups through the 2-, 3-, or 4-position of the pyridyl group. All such configurations are to be construed as within the scope of the present invention.

Examples of heterocyclic or heteroaryl 25 moieties included in the scope of the present invention may include, but are not limited to, the following:

-11-



The term "halo" refers to a halogen atom which may include fluoro, chloro, bromo and iodo.

Preferred halo groups include chloro, bromo and fluoro with chloro and fluoro being especially preferred.

"Pharmaceutically acceptable salt", as used herein, refers to an organic or inorganic salt which is useful in the treatment of a warm-blooded animal. Such salts can be acid or basic addition salts, depending on the nature of the compound of Formula (I). As used herein, "warm blooded animal" includes a mammal, including a member of the human, equine, porcine, bovine, murine, canine or feline species.

In the case of an acidic moiety in a compound
15 of Formula (I), a salt may be formed by treatment of a

- 12 -

compound of Formula (I) with a basic compound, particularly an inorganic base. Preferred inorganic salts are those formed with alkali and alkaline earth metals such as lithium, sodium, potassium, barium and 5 calcium. Preferred organic base salts include, for example, ammonium, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylamine, dibenzyl-ethylenediamine, and the like salts. Other salts of acidic moieties may 10 include, for example, those salts formed with procaine, quinine and N-methylglusoamine, plus salts formed with basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine and arginine. An especially preferred salt is a sodium or potassium salt 15 of a compound of Formula (I).

With respect to basic moieties, a salt is formed by the treatment of a compound of Formula (I) with an acidic compound, particularly an inorganic acid. Preferred inorganic salts of this type may 20 include, for example, the hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric or the like salts. Preferred organic salts of this type, may include, for example, salts formed with formic, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, 25 pamoic, mucic, d-glutamic, d-camphoric, glutaric, glycolic, phthalic, tartaric, lauric, stearic, salicyclic, methanesulfonic, benzenesulfonic, para-toluenesulfonic, sorbic, puric, benzoic, cinnamic and the like organic acids. An especially preferred salt 30 of this type is a hydrochloride or sulfate salt of a compound of Formula (I).

Also encompassed in the scope of the present invention are pharmaceutically acceptable esters of a carboxylic acid or hydroxyl containing group, including 35 a metabolically labile ester or a prodrug form of a compound of Formula (I). A metabolically labile ester

-13-

is one which may produce, for example, an increase in blood levels and prolong the efficacy of the corresponding non-esterified form of the compound. A prodrug form is one which is not in an active form of the molecule as administered but which becomes 5 therapeutically active after some *in vivo* activity or biotransformation, such as metabolism, for example, enzymatic or hydrolytic cleavage. Esters of a compound of Formula (I), may include, for example, the methyl, 10 ethyl, propyl, and butyl esters, as well as other suitable esters formed between an acidic moiety and a hydroxyl containing moiety. Metabolically labile esters, may include, for example, methoxymethyl, ethoxymethyl, iso-propoxymethyl, α -methoxyethyl, groups 15 such as α -((C₁-C₄)alkyloxy)ethyl; for example, methoxyethyl, ethoxyethyl, propoxyethyl, iso-propoxyethyl, etc.; 2-oxo-1,3-dioxolen-4-ylmethyl groups, such as 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl, etc.; C₁-C₄ alkylthiomethyl groups, for example, 20 methylthiomethyl, ethylthiomethyl, isopropylthiomethyl, etc.; acyloxymethyl groups, for example, pivaloyloxymethyl, α -acetoxyethyl, etc.; ethoxycarbonyl-1-methyl; or α -acyloxy- α -substituted methyl groups, for example α -acetoxyethyl.

25 Additionally, the compounds of the instant invention may have one or more asymmetrical carbon atoms and, therefore, may exist in stereoisomeric forms. All stereoisomers are intended to be included within the scope of the present invention. As used, 30 "stereoisomer" or "stereoisomeric" refers to a compound which has the same molecular weight, chemical composition, and constitution as another, but with the atoms grouped such that their orientation in three-dimensional space is different. Such stereoisomers may 35 exist as enantiomeric mixtures, diastereomers or may be

-14-

resolved into individual stereoisomeric components (e.g. specific enantiomers) by methods familiar to one skilled in the art.

Further, the compounds of the invention may 5 exist as crystalline solids which can be crystallized from common solvents such as ethanol, N,N-dimethyl-formamide, water, or the like. Thus, crystalline forms of the compounds of the invention may exist as solvates and/or hydrates of the parent compounds or their 10 pharmaceutically acceptable salts. All of such forms likewise are to be construed as falling within the scope of the invention.

In another aspect, the compounds of the invention are useful for the therapeutic or 15 prophylactic treatment of an inflammatory disease state in warm-blooded animals. For example, as noted, the compounds of the invention may be used as anti-inflammatory agents in an inflammatory disease, especially a mast-cell mediated disease, for example, 20 asthma, allergy or pulmonary disorders.

While it may be possible to administer a compound of the invention alone, normally it will be present as an active ingredient in a pharmaceutical formulation. Thus, in one another embodiment of the 25 invention, there is provided a formulation comprising a compound of Formula (I) in combination, admixture, or associated with a pharmaceutically acceptable carrier, diluent or excipient therefor.

The composition used in the noted therapeutic 30 methods can be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, liposomes, injectable and infusible solutions. The preferred form depends on the intended 35 mode of administration and therapeutic application.

-15-

Considerations for preparing appropriate formulations will be familiar to one skilled in the art and are described, for example, in Goodman and Gilman's: "The Pharmacological Basis of Therapeutics", 8th Ed., 5 Pergamon Press, Gilman et al. eds. (1990); and "Remington's Pharmaceutical Sciences", 18th Ed., Mack Publishing Co., A. Gennaro, ed. (1990). Methods for administration are discussed therein, e.g. for oral, topical, intravenous, intraperitoneal, or intramuscular 10 administration. Pharmaceutically acceptable carriers, diluents, and excipients, likewise, are discussed therein. Typical carriers, diluents, and excipients may include water (for example, water for injection), buffers, lactose, starch, sucrose, and the like.

15 As noted, a compound of the invention can be administered orally, topically or parenterally (e.g. intravenously, intraperitoneally, intramuscularly, subcutaneously, etc.), or inhaled as a dry powder, aerosol, or mist, for pulmonary delivery, for example, 20 in the treatment or prophylaxis of asthma. Such forms of the compounds of the invention may be administered by conventional means for creating aerosols or administering dry powder medications using devices such as for example, metered dose inhalers, nasal sprayers, 25 dry powder inhaler, jet nebulizers, or ultrasonic nebulizers. Such devices optionally may be include a mouthpiece fitted around an orifice. In certain circumstances, it may be desirable to administer the desired compound of the invention by continuous 30 infusion, such as through a continuous infusion pump, or using a transdermal delivery device, such as a patch.

Typically, when the compounds of the invention are to be used in the treatment of asthma or 35 allergic rhinitis, they will be formulated as aerosols. The term "aerosol" includes any gas-borne suspended

-16-

phase of a compound of the invention which is capable of being inhaled into the bronchioles or nasal passages. Specifically, aerosol includes a gas-borne suspension of droplets of the desired compound, as may 5 be produced in a metered dose inhaler or nebulizer, or in a mist sprayer. Aerosol also includes a dry powder composition of a compound of the instant invention suspended in air or other carrier gas, which may be delivered by insufflation from an inhaler device, for 10 example.

For solutions used in making aerosols of the invention, the preferred range of concentration of the compounds of the invention is 0.1-100 milligrams (mg)/milliliter (mL), more preferably 0.1-30 mg/mL, and 15 most preferably 1-10 mg/mL. Usually the solutions are buffered with a physiologically compatible buffer such as phosphate or bicarbonate. The usual pH range is from about 5 to about 9, preferably from about 6.5 to about 7.8, and more preferably from about 7.0 to about 20 7.6. Typically, sodium chloride is added to adjust the osmolarity to the physiological range, preferably within 10% of isotonic. Formulation of such solutions for creating aerosol inhalants is discussed, for example, in Remington's, supra; See, also, Ganderton 25 and Johens, "Drug Delivery to the Respiratory Tract, Ellis Horwood (1987); Gonda, "Critical Review in Therapeutic Drug Carrier Systems" 6 273-313 (1990); and Raeburn et al. J. Pharmacol. Toxicol. Methods. 27 143-159 (1992).

30 Solutions of a compound of the invention may be converted into aerosols by any of the known means routinely used for making aerosol inhalant pharmaceuticals. In general, such methods comprise pressurizing or providing a means of pressurizing a 35 container of the solution, usually with an inert carrier gas, and passing the pressurized gas through a

small orifice, thereby pulling droplets of the solution into the mouth and trachea of the animal to which the drug is to be administered. Typically, a mouthpiece is fitted to the outlet of the orifice to facilitate 5 delivery into the mouth and trachea.

In one embodiment, devices of the present invention comprise solutions of the compounds of the invention connected to or contained within any of the conventional means for creating aerosols in asthma 10 medication, such as metered dose inhalers, jet nebulizers, or ultrasonic nebulizers. Optionally such devices may include a mouthpiece fitted around the orifice.

In the treatment of allergic rhinitis, a 15 device may comprise a solution of a compound of the instant invention in a nasal sprayer.

A dry powder comprising a compound of the invention, optionally with an excipient is another embodiment. This may be administered by a drug powder 20 inhaler containing the described powder.

One skilled in the art will appreciate that the methods of the invention can be used in combination with other agents for the treatment of mast cell mediated inflammatory disorders, and particularly, 25 asthma. β -Adrenergic agonists are especially useful in these combinations, because they provide symptomatic relief of the initial asthmatic response, whereas the compounds of the present invention may provide relief and be better suited to treating the late asthmatic 30 response. Preferred β -adrenergic agonists in these solutions include any of the usual β -agonists employed for the relief of asthma, for example, albuterol, terbutaline, bitolterol mesylate, or the like.

Other agents useful in combination with the 35 compounds of the invention include anticholinergics,

-18-

such as ipratropium bromide, and antiinflammatory corticosteroids (adrenocortical steroids) such as beclomethasone, triamcinolone, flurisolide, or dexamethasone.

5 Further, a compound of the invention may be used in the treatment of immunomediated inflammatory skin conditions, such as urticaria and angioedema, eczematous dermatitis, and hyperproliferative skin disease, for example, psoriasis. In such cases, a
10 compound of the invention could be administered topically so as treat the condition involved. Thus, by treating the animal with a topical preparation comprising a compound of the invention, one would expect a decrease in scaling, erythema, size of the
15 plaques, pruritus and other symptoms associated with the skin condition. The dosage of medicament and the length of time required for treating each patient may vary, but one skilled in the art will recognize that variations may occur from patient to patient and adjust
20 the treatment regimen accordingly.

Thus, in a further embodiment of the invention, there is provided a pharmaceutical preparation for topical application comprising a compound of the invention, typically in concentrations
25 in the range of from about 0.001% to about 10%, in combination with a pharmaceutically acceptable carrier, excipient, or diluent therefor. Such topical preparations can be prepared by combining the compound of the invention with conventional pharmaceutical
30 diluents and carriers commonly used in topical dry, liquid, cream and aerosol formulations. Ointment and creams may be formulated, for example, with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Such bases may include water
35 and/or an oil such as a liquid paraffin or a vegetable oil such as peanut oil or castor oil. Thickening

-19-

agents which may be used according to the characteristics of the base may include, for example, soft paraffin, aluminum stearate, cetostearyl alcohol, propylene glycol, polyethylene glycols, woolfat, 5 hydrogenated lanolin, beeswax, and the like.

Lotions may be formulated with an aqueous or oily base and will include also, in general, one or more of the following: stabilizing agents emulsifying agents, dispersing agents, suspending agents, 10 thickening agents, coloring agents, perfumes, and the like.

Powders may be formed with the aid of any suitable powder bases, for example, talc, lactose, starch and the like. Drops may be formulated with an 15 aqueous base or non-aqueous base also comprising one or more dispersing agents, suspending agents solubilizing agents, and the like.

Any of the formulations of the invention may also include one or more preservatives or 20 bacteriostatic agents, for example, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chlorides, and the like. Additionally, the formulations may contain other active ingredients such as antimicrobial 25 agents, particularly antibiotics, anesthetics, analgesics and antipruritic agents.

The pharmaceutical formulations of the invention may be administered by parenteral or oral administration for prophylactic and/or therapeutic 30 treatment. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending on the method of administration. For example, unit dosage forms suitable for oral administration may include, powders, tablets, pills, 35 capsules and dragées.

-20-


The pharmaceutical formulations can be administered intravenously. Therefore, the invention further provides formulations for intravenous administration which comprise a compound of the invention dissolved or suspended in a pharmaceutically acceptable carrier or diluent therefor. A variety of aqueous carriers can be used, for example, water, buffered water or other buffer solutions, saline, and the like. The resulting aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration. The sterile aqueous solution for the lyophilized product can be packaged as a kit for use with the lyophilized formulation. The compositions can contain pharmaceutically acceptable substances to aid in administration and more closely mimic physiological conditions. Such substances, can include, for example, pH adjusting substances such as acids, bases or buffering agents, tonicity adjusting agents, wetting agents and the like. Such substances may include but are not limited to, for example, sodium hydroxide, hydrochloric acid, sulfuric acid, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, and the like or any other means familiar to one skilled in the art for maintaining pH at a desired level.

For solid formulations, carriers, diluents, and excipients known to one skilled in the art may be used. Such carriers, diluents and excipients may include, for example, mannitol, lactose, starch magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, or other solid polyol sugar, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable formulation is prepared by admixing any of the usual

-21-


carrier, diluents, and excipients, such as those noted, with from about 0.1 to about 95% of a compound of the invention.

The compounds of Formula (I) may be prepared 5 by a variety of methods familiar to one skilled in the art. For example, to prepare a compound of the formula:




the following scheme was used:

10




For those compounds which are amides, for example those of the following structure,

15




the following reaction scheme can be used:

- 22 -




Compounds of Formula (I) in which Ar is an
5 indole, for example of the formula:




may be prepared according to the following general
10 scheme:

- 23 -




Those compounds of Formula (I) in which Ar is a benzothiophene moiety, that is, for example:



5


may be prepared by the following reaction scheme:

- 24 -




Those compounds of Formula (I) in which Ar is a naphthalene moiety, for example:

5



may be prepared in accordance with the following procedure:

- 25 -



In a further optional step, if desired for an appropriate compound of Formula (I), the product of the 5 reaction may be saltified to prepare a pharmaceutically acceptable salt of the invention. Alternatively, and/or additionally, in a further embodiment for an appropriate compound of Formula (I), the product of the reaction may be esterified to prepare a 10 pharmaceutically acceptable ester of the invention as previously defined.

The reactions used to prepare the compounds of Formula (I) may be carried out in any number of solvents in which the reactants may be mutually 15 soluble, including, for example, tetrahydrofuran, benzene, toluene, chloroform, dichloromethane, N,N-dimethylformamide, ethyl ether, dioxane, acetonitrile, or the like. Generally the reaction is carried out at a temperature of between -80° and 150°C, 20 preferably, however, at room temperature.

-26-

The product and intermediates may be isolated or purified using one or more standard purification techniques, including, for example, one or more of simple solvent evaporation, recrystallization, 5 distillation, sublimation, filtration, chromatography, including thin-layer chromatography, HPLC (e.g. reverse phase HPLC using, for example, dilute trifluoroacetic acid in water, acetonitrile, or methanol mixtures as eluent), column chromatography, flash chromatography, 10 radial chromatography, trituration, and the like.

In the preparation of the compounds of the invention, one skilled in the art will understand that one may need to protect or block various reactive functionalities on the starting compounds or 15 intermediates while a desired reaction is carried out on other portions of the molecule. After the desired reactions are complete, or at any desired time, normally such protecting groups will be removed by, for example, hydrolytic or hydrogenolytic means. Such 20 protection and deprotection steps are conventional in organic chemistry. One skilled in the art is referred to "Protective Groups in Organic Chemistry," McOmie, Ed., Plenum Press, New York, New York; and "Protective Groups in Organic Synthesis," Greene, Ed., John Wiley & 25 Sons, New York, NY (1981) for the teaching of protective groups which may be useful in the preparation of compounds of the present invention.

Alternate means beyond those described above for preparing the compounds of the invention will be 30 apparent to one skilled in the art and the noted general procedures are not to be construed as limiting the invention.

-27-

Assay Procedures -- K_i Determinations of Proteases

Protease inhibition was assayed according to published procedures with minor modifications using 5 various proteases and specific chromogenic peptide p-nitroanilide substrates. Assays were performed in Costar ultra-low cluster 96-well microtiter plate (Costar Corning Corp., Cambridge MA). Each protease was incubated with various concentrations of the test 10 compound for 15 min. at 37°C or as otherwise indicated, in specific assay buffer, and the residual activity was then measured by addition of the substrate. p-Nitroaniline produced by the proteolysis was determined by measuring the change in absorbance at 405 15 nm on a SpectraMAX 340 plate reader (Molecular devices, Sunnyvale, CA).

K_i Determinations:

20 1. The inhibition constant, K_i is calculated from individual data points using the equation for a tight-binding inhibitor (See Beith, "Proteinase Inhibitors- Proceedings of 2nd Int. Res. Conference", Fritz, *et al.* eds., New York, p.4463-4469 (1974)):

25
$$v_i/v_o = [((K'_i + [I]_o + [E]_o)^2 - 4[I]_o[E]_o)^{1/2} \cdot (K'_i + [I]_o - [E]_o)] / 2[E]_o$$

where K'_i is apparent inhibition constant; v_i and v_o are the inhibited and uninhibited rates, 30 respectively; $[I]_o$ and $[E]_o$ are the total concentrations of inhibitor and enzyme, respectively.

[note: $[E]_o$ is determined by active site titration of enzyme]

- 28 -

The K_i values are obtained by correcting K_i' values for the effect of substrate concentration according to:

$$K_i = \frac{K_i'}{1 + \frac{[S]}{K_m}}$$

5 (See Beith, Biochem. Med. 32, 387-397 (1984))

2. Other inhibition data ($K_i \gg [E]_0$), the K_i is calculated from using the equations for a competitive inhibitor:

10

$$K_i = \frac{IC_{50}}{1 + \frac{[S]}{K_m}}$$

(See Segel, I.H. (1993) in "Enzyme Kinetics", Wiley Interscience, NY, pp. 106-107)

15

IC_{50} is determined by fitting the individual inhibition data point to Sigmoid or four-parameter curve-fit equations.

20 A. Human Lung Tryptase

Human lung tryptase purchased from Cortex Biochem (San Leandro, CA) was purified further on a Superdex 200 gel-filtration column. The active-site concentration of the enzyme was determined by

25 spectrophotometric titration with 4-nitrophenyl 4'-guanidinobenzoate according to Schwartz, et al., J. Immunol., 144, 2304-2311 (1990). Tryptase activity was measured according to the procedures of Schwartz, et al., J. Biol. Chem., 261, 7372-7379 (1986) (See also, Schwartz, L.B., Methods In Enzymology, 244, 88 (1994)) with minor modifications, using Tosyl-Gly-Pro-Arg-p-nitroanilide ("GPR-pNA", Sigma Chemical Co., St. Louis, Missouri, T-1637) as a chromogenic substrate. The

- 29 -

reaction was performed in 50 mM Tris-HCl, pH 8.0, containing 150 mM NaCl and 0.02% Triton X-100 at 37°C in Costar ultra-low cluster 96-well microtiter plates (Costar Corning Corp., Cambridge, MA). The amount of 5 pNA produced by tryptase was determined by measuring the change in absorbance at 405 nm on a SpectraMAX 340 plate reader (Molecular devices, Sunnyvale, CA). The K_m for the substrate was determined by Lineweaver-Burk analysis from initial velocities of substrate 10 hydrolysis. The inhibition assay was carried out in a total volume of 200 μ L. Tryptase (30 μ L- final concentration 1 nM) was incubated with various concentrations of sample compound (50 μ L) to be tested in the above assay buffer for 5 min. The reaction was 15 started by the addition of substrate GPR-pNA (40 μ L- final concentration 320 μ M), and the residual activity was measured after 15 min. of incubation. The inhibition constant, K_i , was determined by fitting the inhibition data to a two-site competitive binding 20 equation using data analysis program GraphPad PRISM (GraphPad Software, Inc., San Diego, CA).

B. Human Neutrophil elastase

Human Neutrophil elastase activity was determined 25 by using pyroGlu-Pro-Val-pNA in 100 mM Tris-HCl, pH 8.3, 0.96 M NaCl, 1% BSA (See Kramps, et al. Scand. J. Clin. Lab. Invest. 43, 427-432 (1983)).

C. Bovine pancreatic Trypsin

30 Bovine pancreatic Trypsin (TPCK-treated) activity was determined by using N- α -Benzoyl-L-Arg-pNA in 50 mM Tris-HCl, pH 8.2, 20 mM CaCl₂, (See Somorin, et al., J. Biochem. 85, 157-162 (1979)).

-30-

D. Bovine Pancreatic Chymotrypsin

Bovine Pancreatic Chymotrypsin activity was determined by using N-Suc-Ala-Ala-Pro-Phe-pNA in 100 mM Tris-HCl, pH 7.8, 10 mM CaCl₂, (See Delmar, et al., 5 J. Biochem. 85, 157-162 (1979)).

E. Human Neutrophil Cathepsin G

Human Neutrophil Cathepsin G activity was determined by using N-Suc-Ala-Ala-Pro-Phe-pNA in 625 mM 10 Tris-HCl, pH 7.5, 2.5 mM MgCl₂, 0.125% Brij 35 (See Groutas et al., Arch. Biochem. Biophys. 294, 144-146 (1992)).

F. Human plasma plasmin

15 Human plasma plasmin activity was determined by using Tosyl-Gly-Pro-Lys-pNA in 100 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.05% Triton X-100 (See Lottenberg, et al., Meth. Enzymol. 80, 341-361 (1981)).

20 G. Human plasma factor Xa

Human plasma factor Xa activity was determined by using N-Benzoyl-Ile-Glu-Gly-Arg-pNA in 50 mM Tris-HCl, pH 7.8, 200 mM NaCl, 0.05% BSA (See Lottenberg, et al. Meth. Enzymol. 80, 341-361 (1981)).

25

H. Human plasma thrombin

Human plasma thrombin activity was determined by using H-D-Phe-Pip-Arg-pNA in 50 mM Tris-HCl, pH 8.3, 100 mM NaCl, 1% BSA (See Lottenberg, et al., Meth. Enzymol. 80, 341-361 (1981)).

I. Human plasma and r-tissue kallikrein


Human plasma and r-tissue kallikrein activity were determined in 50 mM Tris-HCl, pH 7.8, 200 mM NaCl, 35 0.05% BSA by using H-D-Prolyl-Phe-Arg-pNA and DL-Val-

- 31 -

Leu-Arg-pNA, respectively (See Lottenberg, et al.,
Meth. Enzymol. 80, 341-361 (1981)).


The inhibition constant (K_i) of the test compounds
5 against each proteolytic enzyme was determined
according to Zitnik et al., Biochem. Biophys. Res.
Commun. 232, 687-697 (1997)). The results are provided
below.

- 32 -

K_i(μM)


| <u>R</u> | <u>Tryptase K_i</u> | <u>Trypsin K_i</u> | <u>Thrombin K_i</u> |
|--|-------------------------------|------------------------------|-------------------------------|
| H | 31.4 | - | - |
| CH ₃ | 42.8 | - | - |
| CH ₂ CH ₃ | 7.4 | - | - |
| CH ₂ CH ₂ CH ₃ | 9.6 | - | - |
| Cyclohexyl | 36.9 | - | - |
| CH ₂ CH ₂ (4-Pyridyl) | 1.3 | - | - |
| 4-Piperidinyl(N-benzyl) | 1.7 | - | - |
| CH ₂ (4-Pyridyl) | 4.7 | - | - |
| 2-Naphthyl | 5.2 | - | - |
| 2-Pyridyl | 1.2 | - | - |
| (4-OMe)Ph | 4.5 | - | - |
| CH ₂ Ph(3-Amino) | 0.49 | 7.5 | >100 |
| CH ₂ Ph(4-Amino) | 0.50 | 23.4 | 10.3 |
| (3-Amidino)Ph | 0.52 | 2.2 | >100 |
| (4-Amidino)Ph | 0.97 | 1.7 | >100 |
| (3-Amino)Ph | 0.29 | 14.2 | >100 |
| (4-Amino)Ph | 3.0 | 14.2 | >100 |
| CH ₂ Ph(4-CH ₂ NH ₂) | 2.5 | - | - |
| (4-N(H)SO ₂ CH ₃)Ph | 3.9 | - | - |
| (3-N(H)SO ₂ CH ₃)Ph | 7.7 | - | - |
| (4-N(H)COCH ₃)Ph | 6.4 | - | - |
| (4-SO ₂ NH ₂)Ph | 2.2 | - | - |
| (4-OH)Ph | 2.7 | - | - |
| (3-OH)Ph | 0.57 | 8.7 | >100 |
| 6-Quinoline | 0.34 | 4.6 | >100 |
| 5-Indole | 0.81 | 21.8 | >100 |

- 33 -

 K_i (μM)


| <u>Aryl Moiety</u> | <u>n</u> | <u>m</u> | <u>Tryptase Ki</u> | <u>Trypsin Ki</u> | <u>Thrombin Ki</u> |
|--------------------|----------|----------|--------------------|-------------------|--------------------|
| Indole | 1 | 0 | 0.39 | 4.0 | >100 |
| Benzthiophene | 1 | 1 | 0.09 | 6.4 | >100 |
| Benzthiophene | 0 | 0 | 0.52 | 14.0 | >100 |
| Benzthiophene | 0 | 1 | 0.22 | 9.1 | >100 |
| Naphthalene | 1 | 0 | 1.2 | 2.1 | >100 |
| Naphthalene | 0 | 0 | 0.055 | 0.43 | >100 |
| Naphthalene | 0 | 1 | 0.080 | 1.3 | >100 |

- 34 -



| <u>Aryl Moiety</u> | <u>n</u> | <u>m</u> | <u>Tryptase K_i</u> | <u>Trypsin K_i</u> | <u>Thrombin K_i</u> |
|--------------------|----------|----------|-------------------------------|------------------------------|-------------------------------|
| Indole | 1 | 0 | 0.20 | 3.8 | >100 |
| Indole | 1 | 1 | 0.44 | 3.4 | 65.0 |
| Benzthiophene | 1 | 1 | 0.15 | 7.3 | >100 |
| Benzthiophene | 0 | 1 | 0.44 | 8.8 | >100 |
| Benzthiophene | 0 | 2 | 0.17 | 8.3 | >100 |
| Naphthalene | 0 | 1 | 0.21 | 0.59 | >100 |
| Naphthalene | 0 | 2 | 0.16 | 0.95 | >100 |


- 35 -



| <u>Compound</u> | <u>Tryptase</u> | <u>K_i</u> <u>(μM)</u> |
|--------------------------------|-----------------|----------------------------------|
| X = H n = 0 | | 9.5 |
| X = H n = 1 | | 21.8 |
| X = H n = 2 | | 5.5 |
| X = OMe n = 0 | | 4.5 |
| X = OH n = 0 | | 2.7 |
| X = NH ₂ n = 0 | | 3.0 |
| X = NH ₂ n = 1 | | 0.5 |

| X = H n = 0 | | 9.5 |
| X = H n = 1 | | 21.8 |
| X = H n = 2 | | 5.5 |
| X = OMe n = 0 | | 4.5 |
| X = OH n = 0 | | 2.7 |
| X = NH₂ n = 0 | | 3.0 |
| X = NH₂ n = 1 | | 0.5 |


- 36 -



Arly
or
Hetero-
aryl


| <u>Aryl Moiety</u> | <u>n</u> | <u>Tryptase K_i</u> | <u>Trypsin K_i</u> | <u>Thrombin K_i</u> |
|--------------------|----------|-------------------------------|------------------------------|-------------------------------|
| Naphthalene | 1 | 0.010 | 0.34 | >100 |
| Benzthiophene | 1 | 0.041 | 2.4 | 25.8 |

- 37 -



| | <u>K_i (μM)</u> | | | | | | |
|--|---------------------------|---------|-----------|---------|----------|-------------------|--|
| | Tryptase | Trypsin | Factor Xa | Plasmin | Thrombin | Plasma Kallikrein | Elastase Cathepsin G Chymotrypsin Tissue Kallikrein |
| | 0.041 | 2.4 | 17.7 | 2.7 | 25.8 | 1.6 | >100 |

- 38 -



Tryptase K_i

(μ M)

0.10

-39-

It is to be understood that the above description is intended only to be illustrative of the invention and not restrictive. As will be apparent to one skilled in the art upon reading the description, 5 other embodiments may be prepared and tested using other methods, reagents and procedures familiar to the skilled artisan. The scope of the invention, therefore, should not be determined solely based upon the specific teaching of the description. Instead, the 10 scope of the invention should be determined based upon the teachings of the description along with reference to the appended claims and the full scope of equivalents to which the claims are entitled based upon the knowledge of one of ordinary skill in the art.

- 40 -

We claim:

1. A compound of Formula (I):



wherein

X is -C(O)- , $\text{-}(\text{CH}_2)_n\text{-}$ or $\text{-SO}_2\text{-}$;

10 R is -H , straight or branched chain $(C_1\text{-}C_6)\text{-alkyl}$, $\text{-}(\text{C}_3\text{-}\text{C}_8)\text{-cycloalkyl}$ or $\text{-}(\text{CH}_2)_m\text{-Ar'}\text{-}(Y)_t$;

Ar or Ar' is aryl, heteroaryl, or a 5-membered to 7-membered carbocyclic or heterocyclic ring;

Y is $R^1\text{HN-C(=NH)-}$, $R^1\text{HN-CO-NH-}$, $\text{N}\equiv\text{C-}$ or $R^1\text{HN-}(\text{CH}_2)_v\text{-}$, $(C_1\text{-}C_6)\text{alkyl-SO}_2\text{NH-}$, $\text{-SO}_2\text{NH}_2$,

15 $(C_1\text{-}C_6)\text{alkyl-CONH-}$, -OH , -SH , -CF_3 , -F , -Cl , -Br , -I , -H , $\text{-O}(C_1\text{-}C_6)\text{alkyl}$, aryl, $\text{-}(\text{C}_1\text{-}\text{C}_6)\text{alkylaryl}$, heteroaryl, $(C_1\text{-}C_6)\text{acyloxy}$, $(C_1\text{-}C_6)\text{alkyl}$, $(C_1\text{-}C_6)\text{alkylthio}$, -NO_2 ;

R^1 is -H , $(C_1\text{-}C_4)\text{alkyl-O-CO-}$, $(C_1\text{-}C_4)\text{alkyl-O-}$ or HO- ;

20 j is an integer from 1 to 5, inclusive;

n is an integer between 0 and 10, inclusive;

m is an integer between 0 and 10, inclusive;

t is an integer from 1 to 5, inclusive;

v is an integer between 0 and 6, inclusive;

25 wherein which each Y, Ar, or Ar', is the same or different, provided that if X is -C(O)- , then n is not zero; or, a pharmaceutically acceptable salt, ester, or solvate thereof;

30

2. A compound as claimed in Claim 1 in which Ar is selected from the group consisting of benzothiophenyl, naphthalenyl, indolyl, and benzimidazolyl.

- 41 -

3. A compound as claimed in Claim 2 in which Y is
R¹HN-C(=NH)-.

4. A compound as claimed in Claim 3 in which Ar is
5 benzothiophenyl.

5. A compound as claimed in Claim 3 in which Ar is
naphthalenyl.

10 6. A compound as claimed in Claim 3 in which Ar is
indolyl.

7. A compound as claimed in Claim 3 in which Ar is
benzimidazolyl.

15 8. A formulation comprising a compound of Formula (I):
(Y),-Ar-(CH₂)_n-X-NHR
(I)

20 wherein

X is -C(O)-, -(CH₂)_n- or -SO₂-;

R is -H, straight or branched chain(C₁-C₆)-alkyl, -
(C₁-C₆)-cycloalkyl or -(CH₂)_m-Ar'--(Y);

25 Ar or Ar' is aryl, heteroaryl, or a 5-membered
to 7-membered carbocyclic or heterocyclic ring;

Y is R¹HN-C(=NH)-, R¹HN-CO-NH-, N≡C- or R¹HN-(CH₂)_v-,
(C₁-C₆)alkyl-SO₂NH-, -SO₂NH₂,
(C₁-C₆)alkyl-CONH-, -OH, -SH, -CF₃, -F, -Cl,
-Br, -I, -H, -O(C₁-C₆)alkyl, aryl,
30 - (C₁-C₆)alkylaryl, heteroaryl, (C₁-C₆)acyloxy,
(C₁-C₆)alkyl, (C₁-C₆)alkylthio, -NO₂;

R¹ is -H, (C₁-C₄)alkyl-O-CO-, (C₁-C₄)alkyl-O- or HO-;

j is an integer from 1 to 5, inclusive;

n is an integer between 0 and 10, inclusive;

35 m is an integer between 0 and 10, inclusive;

-42-

t is an integer from 1 to 5, inclusive;
v is an integer between 0 and 6, inclusive;
wherein which each Y, Ar, or Ar', is the same or
different, provided that if X is -C(O)-, then n is
5 not zero; or,
a pharmaceutically acceptable salt, ester, or solvate
thereof, associated with a pharmaceutically acceptable
carrier, diluent or excipient therefor.

10 9. A formulation as claimed in Claim 8 in which Ar is
selected from the group consisting of benzothiophenyl,
naphthalenyl, indolyl, and benzimidazolyl.

15 10. A formulation as claimed in Claim 9 in which Y is
R¹HN-C(=NH)-.


11. A formulation as claimed in Claim 10 in which Ar is
benzothiophenyl.

20 12. A formulation as claimed in Claim 10 in which Ar is
naphthalenyl.

13. A formulation as claimed in Claim 10 in which Ar is
indolyl.

25 14. A formulation as claimed in Claim 10 in which Ar is
benzimidazolyl.

15. A method for treating a warm blooded mammal which
30 comprises administering to said mammal a compound of
Formula (I):



35 wherein

- 43 -

X is $-C(O)-$, $-(CH_2)_n-$ or $-SO_2-$;
R is $-H$, straight or branched chain (C_1-C_6) -alkyl, $-(C_3-C_8)$ -cycloalkyl or $-(CH_2)_n-Ar'-(Y)_t$;
Ar or Ar' is aryl, heteroaryl, or a 5-membered
5 to 7-membered carbocyclic or heterocyclic ring;
Y is $R^1HN-C(=NH)-$, $R^1HN-CO-NH-$, $N\equiv C-$ or $R^1HN-(CH_2)_v-$,
 (C_1-C_6) alkyl- SO_2NH- , $-SO_2NH_2$,
 (C_1-C_6) alkyl- $CONH-$, $-OH$, $-SH$, $-CF_3$, $-F$, $-Cl$,
 $-Br$, $-I$, $-H$, $-O(C_1-C_6)$ alkyl, aryl,
10 $-(C_1-C_6)$ alkylaryl, heteroaryl, (C_1-C_6) acyloxy,
 (C_1-C_6) alkyl, (C_1-C_6) alkylthio, $-NO_2$;
 R^1 is $-H$, (C_1-C_4) alkyl- $O-CO-$, (C_1-C_4) alkyl- $O-$ or $HO-$;
j is an integer from 1 to 5, inclusive;
n is an integer between 0 and 10, inclusive;
15 m is an integer between 0 and 10, inclusive;
t is an integer from 1 to 5, inclusive;
v is an integer between 0 and 6, inclusive;
wherein which each Y, Ar, or Ar', is the same or
different, provided that if X is $-C(O)-$, then n is
20 not zero,; or,
a pharmaceutically acceptable salt, ester, or solvate
thereof.

16. A method as claimed in Claim 15 in which Ar is
25 selected from the group consisting of benzothiophenyl,
naphthalenyl, indolyl, and benzimidazolyl.

17. A method as claimed in Claim 16 in which Y is
R $^1HN-C(=NH)-$.

30 18. A method as claimed in Claim 17 in which Ar is
benzothiophenyl.

19. A method as claimed in Claim 17 in which Ar is
35 naphthalenyl.

- 44 -

20. A method as claimed in Claim 17 in which Ar is indolyl.

5 21. A method as claimed in Claim 17 in which Ar is benzimidazolyl.

22. A method as claimed in Claim 17 in which the mammal has an inflammatory disease.

10 23. A method as claimed in Claim 17 in which the mammal has a mast cell mediated disease.

24. A method as claimed in Claim 17 in which the 15 disease involves tryptase activation.

25. A method as claimed in Claim 24 in which the disease is asthma, allergic rhinitis, rheumatoid 20 arthritis, dermatological diseases, multiple sclerosis, conjunctivitis, inflammatory bowel disease, anaphylaxis, osteoarthritis, peptic ulcers, or cardiovascular disease.

26. A method for preventing an inflammatory response 25 in a warm blooded mammal which comprises administering to said mammal a compound of Formula (I):

(Y), -Ar- (CH₂)_n -X -NHR
30 (I)

wherein

X is -C(O)-, -(CH₂)_n- or -SO₂-;

R is -H, straight or branched chain(C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl or -(CH₂)_m-Ar'- (Y),;

35 Ar or Ar' is aryl, heteroaryl, or a 5-membered

-45-

to 7-membered carbocyclic or heterocyclic ring;
Y is $R^1HN-C(=NH)-$, $R^1HN-CO-NH-$, $N\equiv C-$ or $R^1HN-(CH_2)_j-$,

(C_1-C_6) alkyl- SO_2NH- , $-SO_2NH_2$,

(C_1-C_6) alkyl- $CONH-$, $-OH$, $-SH$, $-CF_3$, $-F$, $-Cl$,

5 $-Br$, $-I$, $-H$, $-O(C_1-C_6)$ alkyl, aryl,
 $-(C_1-C_6)$ alkylaryl, heteroaryl, (C_1-C_6) acyloxy,
 (C_1-C_6) alkyl, (C_1-C_6) alkylthio, $-NO_2$;

R^1 is $-H$, (C_1-C_6) alkyl- $O-CO-$, (C_1-C_6) alkyl- $O-$ or $HO-$;

j is an integer from 1 to 5, inclusive;

10 n is an integer between 0 and 10, inclusive;

m is an integer between 0 and 10, inclusive;

t is an integer from 1 to 5, inclusive;

v is an integer between 0 and 6, inclusive;

wherein which each Y, Ar, or Ar', is the same or

15 different, provided that if X is $-C(O)-$, then n is
not zero; or,

a pharmaceutically acceptable salt, ester, or solvate
thereof.

20 27. A method as claimed in Claim 26 in which Ar is
selected from the group consisting of benzothiophenyl,
naphthalenyl, indolyl, and benzimidazolyl.

25 28. A method as claimed in Claim 27 in which Y is
 $R^1HN-C(=NH)-$.

29. A method as claimed in Claim 28 in which Ar is
benzothiophenyl.

30 30. A method as claimed in Claim 28 in which Ar is
naphthalenyl.

31. A method as claimed in Claim 28 in which Ar is
indolyl.

INTERNATIONAL SEARCH REPORT

Intern. Appl. No
PCT/US 98/23362

| A. CLASSIFICATION OF SUBJECT MATTER | | | | | |
|-------------------------------------|------------|------------|------------|------------|------------|
| IPC 6 | C07D235/16 | C07D209/18 | C07D209/42 | C07D333/60 | C07D333/62 |
| | C07D235/14 | C07D209/08 | C07D401/12 | C07D403/12 | C07D409/12 |
| | C07C257/18 | A61K31/155 | A61K31/40 | A61K31/415 | A61K31/38 |

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | <p>"The Merck Index, 9th edition" 1976, MERCK & CO., INC., RAHWAY, N. J., U.S.A. XP002093171</p> <p>see page 58, compounds 428, 429, 433; page 60, compound 442; page 62, compounds 458, 459, 462; page 63, compound 466; pages 63-64, compound 470; page 64, compound 477; page 66, compound 485; page 67, compounds 494, 496; pages 89-90, compound 692; pages 90-91, compound 700; page 156, compound 1213; page 162, compound 1248; page 169, compound 1319; page 180, compound 1403; page 239, compound 1866; page 261, compound 2039; page 269, compound 2090; page 307, compound 2353; page 341-342, compound 2619; page 380, compound 2866; page 391, compound 2937; pages 402-403, compound 3026; page 415, compound 3124; page 423, compound 3171; -/-</p> | 1,2,8,9 |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

12 February 1999

26/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

1

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 98/23362

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| | page 435, compound 3266; pages 435-436, compound 3267; page 455, compound 3422; page 496, compound 3694; page 509, compound 3826; page 518, compound 3890; page 539, compound 4054; pages 620-621, compound 4605; page 714, compound 5308; page 736, compound 5472; page 768, compound 5752; page 785, compound 5878; page 818, compound 6137; page 832, compounds 6225, 6226; page 855, compounds 6403, 6404, 6405; page 864, compound 6475; page 937-938, compounds 7016, 7017, 7018; page 943, compound 7051; page 945, compound 7067; pages 950-951, compound 7114; page 975, compound 7282; page 1040, compound 7800; page 1095, compound 8209; page 1155, compound 8717; page 1226, compounds 9232, 9233, 9234; page 1256, compound 9456; page 1261, compound 9489; page 1292, compound 9689 --- | |
| Y | EP 0 802 179 A (TORII PHARMACEUTICAL CO., LTD.) 22 October 1997 see claims 1,3-5 | 1-3,5, 8-10,12 |
| X | see claim 7 --- | 1-3,5 |
| Y | EP 0 048 433 A (TORII & CO., LTD.) 31 March 1982 see abstract; claims 1,13 | 1-3,5, 8-10,12 |
| Y | DE 34 27 865 A (TORII & CO.) 6 February 1986 see page 19 - page 21; claims 1,6 | 1-3,5, 8-10,12 |
| Y | EP 0 556 024 A (TORII & CO., LTD.) 18 August 1993 see page 3, line 40 - line 46; claims 1,12; table 1 --- | 1-3,5, 8-10,12 |
| A | WO 97 37969 A (ONO PHARMACEUTICAL CO., LTD.) 16 October 1997 see the whole document --- | 1,3,8,10 |
| A | EP 0 540 051 A (DAIICHI PHARMACEUTICAL CO., LTD.) 5 May 1993 see claims 1,6,7 --- | 1,3,8,10 |
| A | US 5 481 021 A (R. B. GARLAND ET AL.) 2 January 1996 see claims --- | 1,3,8,10 |
| A | T. A. FAIRLEY ET AL.: JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 12, 1993, pages 1746-53, XP002067234 --- | 1,3 |

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 98/23362

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | US 5 525 623 A (K. SPEAR ET AL.) 11 June 1996 cited in the application see abstract; tables I,II,III & WO 94 20527 A cited in the application ---- | 1,8 |
| A | WO 94 27958 A (BOEHRINGER MANNHEIM GMBH) 8 December 1994 cited in the application see claims 1,3,4 ---- | 1,3,8,10 |
| A | WO 96 09297 A (ARRIS PHARMACEUTICAL CORP.) 28 March 1996 cited in the application see abstract; claim 1 ---- | 1,8 |
| A,P | WO 98 01428 A (DU PONT MERCK PHARMACEUTICAL CO.) 15 January 1998 cited in the application see abstract; tables ----- | 1,8 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/23362

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 15-35 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Claims Nos.: 15-35

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Claims Nos.: 1

Because of the vast number of compounds comprised by the definitions given in claim 1 (claim 1 comprises e.g. even the well-known aniline) it is not clear for which subject-matter protection is actually sought (Art. 6 PCT). Thus, for technical and economic reasons, a complete and exhaustive search was not possible (see Art. 17(2) PCT; Guidelines B III, 2.1). Consequently, the search was mainly based (but not restricted to) the examples given in the description.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 98/23362

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|--|------------------|---|--|--|
| EP 802179 | A 22-10-1997 | AU 686104 B AU 4355696 A CA 2208032 A WO 9620917 A | | 05-02-1998 24-07-1996 11-07-1996 11-07-1996 |
| EP 48433 | A 31-03-1982 | JP 1655183 C JP 3007663 B JP 57179146 A JP 1332984 C JP 57053454 A JP 61001063 B AT 20051 T AU 527371 B AU 7506281 A CA 1177488 A CS 228534 B DD 201779 A DK 410681 A, B, FI 812876 A, B, GB 2083818 A, B SU 1176832 A US 4454338 A US 4532255 A ZA 8106363 A | | 13-04-1992 04-02-1991 04-11-1982 28-08-1986 30-03-1982 13-01-1986 15-06-1986 03-03-1983 25-03-1982 06-11-1984 14-05-1984 10-08-1983 17-03-1982 17-03-1982 31-03-1982 30-08-1985 12-06-1984 30-07-1985 29-09-1982 |
| DE 3427865 | A 06-02-1986 | NONE | | |
| EP 556024 | A 18-08-1993 | JP 5213927 A AT 125806 T AU 652076 B AU 2537892 A CA 2079267 A DE 69300307 D DE 69300307 T DK 556024 T FI 925311 A MX 9205914 A NO 300633 B PL 297964 A RU 2096410 C US 5532267 A ZA 9207646 A | | 24-08-1993 15-08-1995 11-08-1994 12-08-1993 11-08-1993 07-09-1995 25-01-1996 18-09-1995 11-08-1993 01-09-1993 30-06-1997 18-10-1993 20-11-1997 02-07-1996 13-04-1993 |
| WO 9737969 | A 16-10-1997 | EP 0893437 A | | 27-01-1999 |
| EP 540051 | A 05-05-1993 | AT 136293 T AU 666137 B AU 2747092 A CA 2081836 A CN 1072677 A CN 1168885 A CN 1168886 A CZ 284381 B DE 69209615 D DE 69209615 T DK 540051 T ES 2088073 T FI 924932 A | | 15-04-1996 01-02-1996 06-05-1993 01-05-1993 02-06-1993 31-12-1997 31-12-1997 11-11-1998 09-05-1996 09-01-1997 06-05-1996 01-08-1996 01-05-1993 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No
PCT/US 98/23362

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|--|------------------|-------------------------|--|------------------|
| EP 540051 | A | GR 3019832 T | | 31-08-1996 |
| | | HR 921147 A | | 31-10-1995 |
| | | HU 65890 A | | 28-07-1994 |
| | | JP 10291931 A | | 04-11-1998 |
| | | JP 5208946 A | | 20-08-1993 |
| | | MX 9206295 A | | 01-08-1993 |
| | | NO 302948 B | | 11-05-1998 |
| | | NZ 244936 A | | 26-05-1995 |
| | | PL 170312 B | | 29-11-1996 |
| | | US 5576343 A | | 19-11-1996 |
| | | US 5620991 A | | 15-04-1997 |
| | | ZA 9208276 A | | 06-05-1993 |
| US 5481021 | A 02-01-1996 | AT 114670 T | | 15-12-1994 |
| | | AU 662142 B | | 24-08-1995 |
| | | AU 1666692 A | | 06-10-1992 |
| | | CA 2099994 A | | 07-09-1992 |
| | | DE 69200766 D | | 12-01-1995 |
| | | DE 69200766 T | | 04-05-1995 |
| | | DK 574545 T | | 30-01-1995 |
| | | EP 0502536 A | | 09-09-1992 |
| | | EP 0574545 A | | 22-12-1993 |
| | | ES 2065182 T | | 01-02-1995 |
| | | JP 6505497 T | | 23-06-1994 |
| | | MX 9203551 A | | 01-09-1992 |
| | | WO 9215607 A | | 17-09-1992 |
| US 5525623 | A 11-06-1996 | AU 683459 B | | 13-11-1997 |
| | | AU 6364794 A | | 26-09-1994 |
| | | CN 1119019 A | | 20-03-1996 |
| | | CZ 9502321 A | | 17-07-1996 |
| | | EP 0688337 A | | 27-12-1995 |
| | | FI 954245 A | | 28-09-1995 |
| | | JP 8507768 T | | 20-08-1996 |
| | | NO 953522 A | | 07-09-1995 |
| | | NZ 263084 A | | 22-08-1997 |
| | | PL 310559 A | | 27-12-1995 |
| | | SK 112995 A | | 01-10-1996 |
| | | WO 9420527 A | | 15-09-1994 |
| WO 9427958 | A 08-12-1994 | DE 4316922 A | | 24-11-1994 |
| | | AU 6927894 A | | 20-12-1994 |
| WO 9609297 | A 28-03-1996 | AU 694275 B | | 16-07-1998 |
| | | AU 3718095 A | | 09-04-1996 |
| | | CA 2200561 A | | 28-03-1996 |
| | | CN 1160398 A | | 24-09-1997 |
| | | CZ 9700870 A | | 12-11-1997 |
| | | EP 0782571 A | | 09-07-1997 |
| | | FI 971171 A | | 20-03-1997 |
| | | HR 950499 A | | 31-08-1997 |
| | | HU 77770 A | | 28-08-1998 |
| | | JP 10506390 T | | 23-06-1998 |
| | | LT 97065 A, B | | 25-08-1997 |
| | | LV 11865 A | | 20-10-1997 |
| | | LV 11865 B | | 20-01-1998 |
| | | NO 971305 A | | 06-05-1997 |
| | | PL 319587 A | | 18-08-1997 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 98/23362

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|--|------------------|-------------------------|------------------------|--------------------------|
| WO 9609297 A | | SI ZA | 9520101 A 9508028 A | 31-12-1997 18-04-1996 |
| WO 9801428 A | 15-01-1998 | AU | 3645697 A | 02-02-1998 |